Skip to main content

Table 1 Treatment characteristics of clinical trials included in this study

From: Meta-analysis: Adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus

Study HBeAg status
(+/-)
Strategy for therapy Primary efficacy measures Secondary efficacy measures
Rapti (2007) - ADV 10 mg vs. ADV 10 mg + LAM 100 mg BR, VR ADV-R, AE
Chen (2008) + ADV 10 mg vs. ADV 10 mg + LAM 100 mg BR, VR, eAg-C, eAg-SC No
Yang (2008) +/- ADV 10 mg vs. ADV 10 mg + LAM 100 mg BR, VR, eAg-C, eAg-SC ADV-R, AE
Peters (2004) + ADV 10 mg vs. ADV 10 mg + LAM 100 mg BR, VR, eAg-C, eAg-SC ADV-R, AE
Xiao (2008) + ADV 10 mg (with or without an overlap period with LAM) vs. ADV 10 mg + LAM 100 mg BR, VR, eAg-C, eAg-SC No
Ijaz (2008) - ADV 10 mg vs. ADV 10 mg + LAM 100 mg VR ADV-R
  1. ADV, adefovir dipivoxil; LAM, lamivudine; eAg-C, hepatitis B e antigen (HBeAg) clearance; eAg-SC, HBeAg seroconversion; ADV-R, ADV resistance; BR, biochemical response; VR, virologic response; AE, adverse event.